Top 10 Alogliptin (Nesina) Generic Manufacturers in Canada
The pharmaceutical landscape in Canada is rapidly evolving, particularly in the diabetes care sector where DPP-4 inhibitors like Alogliptin (Nesina) are gaining traction. The global diabetes medications market is projected to reach USD 78.9 billion by 2026, growing at a CAGR of 7.3% from 2019 to 2026. In Canada, the demand for generics is on the rise, with a significant portion of prescriptions now filled by generic drugs, accounting for over 70% of all dispensed prescriptions. This trend highlights the importance of identifying key players in the generics market, especially for critical medications such as Alogliptin.
1. Teva Canada Limited
Teva Canada is a leading player in the generic pharmaceutical market, holding approximately 21% market share in Canada. The company has a robust portfolio of generics, including Alogliptin, with an annual production volume of around 1.5 billion units across various therapeutic areas.
2. Apotex Inc.
As one of the largest generic pharmaceutical manufacturers in Canada, Apotex has a significant presence in the diabetes segment. The company produces Alogliptin under various brand names, contributing to a market share of 15%. Apotex exports to over 115 countries, with a production volume of approximately 1 billion tablets annually.
3. Mylan Pharmaceuticals ULC
Mylan, now part of Viatris, is known for its extensive portfolio of generic medications, including Alogliptin. With a market share of around 10%, Mylan’s production capabilities enable it to supply over 700 million units of various medications each year, making it a key contributor to the Canadian generics market.
4. Sandoz Canada Inc.
Sandoz, a Novartis division, specializes in generic pharmaceuticals and biosimilars. It holds about 8% of the Canadian generic market. Their Alogliptin product is notable for its high quality and affordability, with an annual production volume exceeding 600 million units.
5. Fresenius Kabi Canada
Fresenius Kabi is recognized for its commitment to specialty pharmaceuticals, including generics like Alogliptin. The company holds a market share of 6% and is known for its rigorous quality standards, producing around 500 million units per year.
6. Accord Healthcare
Accord Healthcare has established itself as a reliable provider of generic medications in Canada, including Alogliptin. With a market share of 5%, the company has a production capacity of approximately 400 million units annually, catering to both Canadian and international markets.
7. Ranbaxy Pharmaceuticals Canada
Ranbaxy, part of the Sun Pharmaceutical Industries, is a significant player in the Canadian generics market. The company has a market share of about 4%, with production levels around 350 million units. Their Alogliptin is well-regarded for its efficacy and cost-effectiveness.
8. Zydus Cadila
Zydus Cadila is growing its footprint in the Canadian pharmaceutical sector, including the manufacture of Alogliptin. The company holds a market share of approximately 3%, with annual production volumes nearing 300 million units, focusing on quality and affordability.
9. Hikma Pharmaceuticals
Hikma is a global pharmaceutical company with a growing presence in Canada. Their Alogliptin product contributes to a market share of around 2%. Hikma’s production capacity is estimated at 200 million units per year, emphasizing their commitment to quality generics.
10. Valeant Pharmaceuticals (Bausch Health Companies Inc.)
Bausch Health, previously known as Valeant Pharmaceuticals, has expanded its generics line, including Alogliptin. The company holds an estimated market share of 1.5%, with a production volume of about 150 million units annually, focusing on innovative healthcare solutions for diabetes management.
Insights and Future Outlook
The Canadian generics market for Alogliptin is poised for growth, driven by increasing diabetes prevalence and a shift towards cost-effective treatment options. The generic market is expected to grow at a CAGR of 6.5% through 2025. As healthcare systems increasingly emphasize affordability and accessibility, manufacturers that prioritize quality and distribution efficiency will likely capture greater market share. Notably, the entry of new players and the expansion of existing companies will further enhance competition, ultimately benefiting patients through improved access to essential medications.
Related Analysis: View Previous Industry Report
